Rockefeller Capital Management’s Allogene Therapeutics ALLO Stock Holding History

Rockefeller Capital Management’s Portfolio ALLO Stock Details ALLO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$26K	Sell	12,499 -1,369	-10%	-$3.01K	﹤0.01%	3649
2026 Q1	$33.8K	Buy	13,868 +5,972	+76%	+$12K	﹤0.01%	3466
2025 Q4	$10.8K	Buy	7,896 +646	+9%	+$852	﹤0.01%	3778
2025 Q3	$8.99K	Buy	+7,250	New	+$8.64K	﹤0.01%	3686
2023 Q2	–	Sell	-14,702	Closed	-$72K	–	1814
2023 Q1	$72K	Buy	14,702 +77	+0.5%	+$494	﹤0.01%	1909
2022 Q4	$91K	Buy	14,625 +542	+4%	+$5.02K	﹤0.01%	2077
2022 Q3	$151K	Buy	14,083 +1,248	+10%	+$17K	﹤0.01%	1779
2022 Q2	$146K	Sell	12,835 -27,754	-68%	-$246K	﹤0.01%	1752
2022 Q1	$369K	Buy	40,589 +7,943	+24%	+$82.7K	﹤0.01%	1440
2021 Q4	$486K	Buy	32,646 +22,646	+226%	+$400K	﹤0.01%	1331
2021 Q3	$257K	Buy	+10,000	New	+$237K	﹤0.01%	1502
2021 Q1	–	Sell	-3,054	Closed	-$77K	–	3236
2020 Q4	$77K	Buy	+3,054	New	+$99.5K	﹤0.01%	1541

Other funds holding ALLO

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Pfizer New York $170M AUM 191.09% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

TGA

TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return

SCM

Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Rockefeller Capital Management's ALLO Position: Q2 2026 in Review

Rockefeller Capital Management reduced its Allogene Therapeutics (ALLO) stake by 9.9% in Q2 2026, selling an estimated $3.01K and leaving 12,499 shares worth $26K. The position accounts for ﹤0.01% of the portfolio, ranked #3649.

Rockefeller Capital Management first reported a position in ALLO in Q4 2020 and has held it in 12 quarters since. The position peaked at $486K in Q4 2021. 209 funds tracked by Wall St. Rank hold ALLO as of Q2 2026.

Rockefeller Capital Management held 12,499 shares of Allogene Therapeutics worth $26K as of Q2 2026.
Rockefeller Capital Management sold 1,369 Allogene Therapeutics shares in Q2 2026, an estimated $3.01K.
Allogene Therapeutics made up ﹤0.01% of Rockefeller Capital Management's portfolio in Q2 2026, its #3649 holding.
Rockefeller Capital Management first reported a position in Allogene Therapeutics in Q4 2020 and has held it in 12 quarters since.
Rockefeller Capital Management's Allogene Therapeutics position peaked at $486K in Q4 2021.
209 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q2 2026.

Based on Rockefeller Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.